Contrast magnetic resonance imaging for measurement of cartilage glycosaminoglycan content in dogs: A pilot study

Summary

Objective: To assess the ability of a contrast-enhanced magnetic resonance imaging (MRI) technique to quantitatively determine glycosaminoglycan content in canine articular cartilage.

Methods: Fifty-four full-thickness cartilage discs were collected from the femorotibial and scapulohumeral joints of three adult dogs immediately following euthanasia. One set of discs from each dog was analysed for glycosaminoglycan content using a colourimetric laboratory assay. The remaining position-matched set of discs from contralateral limbs underwent pre- and post-contrast gadolinium-enhanced MRI, using repeated saturation recovery pulse sequences which were used to generate calculated T1 maps of the cartilage discs. Linear regression analysis was then performed relating delayed gadolinium-enhanced MRI T1 calculated signal intensity to the cartilage glycosaminoglycan content normalized to DNA content. Repeatability of triplicate measurements was estimated by calculating the coefficient of variation.

Results: Mean coefficient of variation estimates for the gadolinium-enhanced MRI T1 signal intensity values for nine sampling sites from three dogs ranged from 5.9% to 7.5%. Gadolinium-enhanced MRI T1 signal intensity was significantly correlated (p <0.05) with normalized glycosaminoglycan content in two dogs (r = 0.79, p = 0.011; r = 0.78, p = 0.048), but not in the third dog (r = 0.53, p = 0.071).

Clinical significance: Gadolinium-enhanced MRI assessment of cartilage may be predictive of glycosaminoglycan content and therefore offer an in vivo assessment of changes in cartilage characteristics over time. Additional studies appear indicated to determine the reliability and clinical applicability of gadolinium-enhanced MRI in detecting changes in cartilage over time.

Keywords

Canine - cartilage - gadolinium - Magnetic resonance imaging - glycosaminoglycan

• References

• 1 Winalski CS, Aliabadi P, Wright RJ. et al. Enhancement of joint fluid with intravenously administered gadopentetate dimeglumine: technique, rationale, and implications. Radiology 1993; 187: 179-185.
• 2 Buckwalter JA, Martin JA. Osteoarthritis. Adv Drug Deliv Rev 2006; 58: 150-167.
• 3 Blackburn Jr. WD, Chivers S, Bernreuter W. Cartilage imaging in osteoarthritis. Semin Arthritis Rheum 1996; 25: 273-281.
• 4 Bashir A, Gray ML, Burstein D. Gd-DTPA2- as a measure of cartilage degradation. Magn Reson Med 1996; 36: 665-673 and: Erratum. Magn Reson Med 1996; 36: 964.
• 5 Goodrich L, Nixon A. Medical treatment of osteoarthritis in the horse - A review. Vet J 2006; 171: 51-69.
• 6 van Weeren P, de Grauw J. Pain in Osteoarthritis. Vet Clin N Am-Equine 2010; 26: 619-642.
• 7 Sanderson R, Beata C, Flipo R. et al. Systematic review of the management of canine osteoarthritis. Vet Rec 2009; 164: 418-424.
• 8 Buckwalter JA, Mankin HJ. Articular cartilage: tissue design and chondrocyte-matrix interactions. Instr Course Lect 1998; 47: 477-486.
• 9 Bashir A, Gray ML, Boutin RD. et al. Glycosaminoglycan in articular cartilage: in vivo assessment with delayed Gd(DTPA)(2)-enhanced MR imaging. Radiology 1997; 205: 551-558.
• 10 Gillis A, Bashir A, McKeon B. et al. Magnetic resonance imaging of relative glycosaminoglycan distribution in patients with autologous chondrocyte transplants. Invest Radiol 2001; 36: 743-748.
• 11 Taylor C, Carballido-Gamio J, Majumdar S. et al. Comparison of quantitative imaging of cartilage for osteoarthritis: T2, T1ρ, dGEMRIC and contrast-enhanced computed tomography. Magn Reson Imaging 2009; 27: 779-784.
• 12 Nieminen M, Rieppo J. Spatial assessment of articular cartilage proteoglycans with Gd-DTPA-enhanced T1 imaging. Magnet Reson Med 2002; 48: 640-648.
• 13 Mamisch T, Dudda M, Hughes T. et al. Comparison of delayed gadolinium enhanced MRI of cartilage (dGEMRIC) using inversion recovery and fast T1 mapping sequences. Magnet Reson Med 2008; 60: 768-773.
• 14 Sabiston P, Adams M, Ho Y. Automation of 1,9-dimethylmethylene blue dye-binding assay for sulfated glycosaminoglycans with application to cartilage microcultures. Anal Biochem 1984; 149: 543-548.
• 15 Mort J, Roughley P. Measurement of glycosaminoglycan release from cartilage explants. In: Cope AP. editor. Arthritis Research, Methods in Molecular Medicine. Volume 135. New York: Humana; 2007; pg. 201-209.
• 16 Boesen M, Jensen K, Qvistgaard E. et al. Delayed gadolinium-enhanced magnetic resonance imaging (dGEMRIC) of hip joint cartilage: better cartilage delineation after intra-articular than intravenous gadolinium injection. Acta Radiol 2006; 47: 391-396.
• 17 Kwack KS, Cho JH, Kim MMS. et al. Comparison study of intra-articular and intravenous gadolinium-enhanced magnetic resonance imaging of cartilage in a canine model. Acta Radiol 2008; 49: 65-74.
• 18 Williams A, Oppenheimer R, Gray M. et al. Differential recovery of glycosaminoglycan after IL-1-induced degradation of bovine articular cartilage depends on degree of degradation. Arthritis Res Ther 2003; 5: R97-105.
• 19 Woertler K, Buerger H, Moeller J. et al. Patellar articular cartilage lesions: in vitro MR imaging evaluation after placement in gadopentetate dimeglumine solution. Radiology 2004; 230: 768-773.
• 20 Nojiri T, Watanabe N, Namura T. et al. Utility of delayed gadolinium-enhanced MRI (dGEMRIC) for qualitative evaluation of articular cartilage of patellofemoral joint. Knee Surg Sport Tr A 2006; 4: 1-6.
• 21 Wucherer K, Ober C, Conzemius M. The use of delayed gadolinium-enhanced magnetic resonance imaging of cartilage and T2 mapping to evaluate articular cartilage in the normal canine elbow. Vet Radiol Ultrasoun 2012; 53: 57-63.